
Results
9
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
9 companies
AbbVie
Market Cap: US$394.1b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$225.42
7D
4.7%
1Y
19.0%
Merck
Market Cap: US$295.2b
Operates as a healthcare company worldwide.
MRK
US$119.60
7D
3.4%
1Y
47.0%
Travere Therapeutics
Market Cap: US$4.4b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$48.57
7D
13.1%
1Y
221.0%
Mesa Laboratories
Market Cap: US$599.2m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$109.03
7D
2.2%
1Y
4.5%
MannKind
Market Cap: US$1.0b
A biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
MNKD
US$3.57
7D
4.1%
1Y
-8.9%
Waters
Market Cap: US$35.7b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$371.15
7D
-0.2%
1Y
6.1%
BioLife Solutions
Market Cap: US$1.3b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$27.55
7D
0.2%
1Y
15.2%
Repligen
Market Cap: US$7.1b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$130.13
7D
7.4%
1Y
-2.1%
Sotera Health
Market Cap: US$4.5b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$16.53
7D
10.1%
1Y
34.4%